{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:58:10Z","timestamp":1785398290198,"version":"3.56.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Cutaneous lupus erythematosus (CLE) is a heterogeneous inflammatory skin disease that can be disfiguring and profoundly affect patient quality of life. CLE is frequently challenging to manage and may remain refractory even when systemic disease is well controlled. Currently, no therapies are FDA-approved specifically for isolated CLE. This review summarizes established treatment approaches and highlights emerging targeted therapies informed by recent advances in disease pathogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Recent studies expand the role of biologics and highlight the promise of additional interferon (IFN)-targeted therapies for the treatment of refractory CLE. Therapies targeting B cells, plasmacytoid dendritic cells, the type I IFN receptor, and downstream pathways \u2013 including JAK, TYK2, TLR7\/8, and IRAK4 inhibitors \u2013 continue to broaden therapeutic options. Importantly, the incorporation of skin-specific outcome measures into systemic lupus erythematosus (SLE) clinical trials has supported the evaluation of cutaneous responses within broader SLE programs, which in turn has expanded the use of newer SLE therapies for CLE. This evolution in trial design may also facilitate future FDA approval pathways for treatments aimed at isolated CLE, an area currently lacking approved therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A deepening understanding of CLE pathogenesis has yielded multiple promising new treatments for CLE, with targeting of type I IFN and downstream signaling proving especially fruitful.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001175","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:00:08Z","timestamp":1781877608000},"page":"349-357","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["New approaches to the management of cutaneous lupus"],"prefix":"10.1097","volume":"38","author":[{"given":"Kathie","family":"Velez","sequence":"first","affiliation":[{"name":"Department of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace A.","family":"Osborne","sequence":"additional","affiliation":[{"name":"Department of Dermatology"},{"name":"Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison C.","family":"Billi","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"R1-20260730","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1111\/ijd.17178","article-title":"Systemic correlates of cutaneous manifestations of lupus erythematosus","volume":"63","author":"Heil","year":"2024","journal-title":"Int J Dermatol"},{"key":"R2-20260730","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41584-025-01318-6","article-title":"Cutaneous lupus erythematosus \u2013 from pathogenesis to targeted therapy","volume":"21","author":"Klein","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"R3-20260730","doi-asserted-by":"crossref","first-page":"e908","DOI":"10.1111\/jdv.20646","article-title":"Cutaneous lupus matters: independent and additive quality-of-life burden shown by 2022 WLFGI Survey","volume":"39","author":"Zhang","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R4-20260730","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jamadermatol.2024.4991","article-title":"Incidence and prevalence of atherosclerotic cardiovascular disease in cutaneous lupus erythematosus","volume":"161","author":"Chen","year":"2025","journal-title":"JAMA Dermatol"},{"key":"R5-20260730","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/archdermatol.2011.342","article-title":"Impact of smoking in cutaneous lupus erythematosus","volume":"148","author":"Piette","year":"2012","journal-title":"Arch Dermatol"},{"key":"R6-20260730","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jamadermatol.2024.2355","article-title":"Area deprivation and disease severity in adult patients with discoid lupus erythematosus","volume":"160","author":"Faden","year":"2024","journal-title":"JAMA Dermatol"},{"key":"R7-20260730","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/archdermatol.2011.191","article-title":"Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis","volume":"147","author":"Chang","year":"2011","journal-title":"Arch Dermatol"},{"key":"R8-20260730","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/biom15091250","article-title":"Ashes to rashes: an exploration of the intersection between smoking and cutaneous lupus erythematosus","volume":"15","author":"Homer","year":"2025","journal-title":"Biomolecules"},{"key":"R9-20260730","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1097\/MS9.0000000000003047","article-title":"Efficacy and safety of calcineurin inhibitors in cutaneous lupus: a systematic review and brief meta-analysis of recommended concentration, type, and outcomes","volume":"87","author":"Alshathri","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"R10-20260730","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/ced\/llae236","article-title":"Efficient topical treatments of cutaneous lupus erythematosus: a systematic review and network-meta-analysis","volume":"50","author":"Fukasawa","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"R11-20260730","first-page":"188","article-title":"Novel clinical applications of topical ruxolitinib: a case series","volume":"23","author":"Zundell","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"R12-20260730","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamadermatol.2021.1198","article-title":"Use of tofacitinib, 2%, ointment for periorbital discoid lupus erythematosus","volume":"157","author":"Mazori","year":"2021","journal-title":"JAMA Dermatol"},{"key":"R13-20260730","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2019.07.027","article-title":"An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review","volume":"82","author":"Shipman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R14-20260730","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaad.2025.02.066","article-title":"Early initiation of hydroxychloroquine in cutaneous lupus erythematosus to prevent progression to systemic lupus erythematosus: a long-term follow-up study","volume":"93","author":"Bar","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R15-20260730","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R16-20260730","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaad.2017.09.061","article-title":"Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study","volume":"78","author":"Mittal","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R17-20260730","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaad.2021.09.017","article-title":"Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: a cohort study","volume":"87","author":"Keyes","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R18-20260730","first-page":"e93114","article-title":"Bullous systemic lupus erythematosus as the initial presentation of systemic lupus erythematosus","volume":"17","author":"Kydyralieva","year":"2025","journal-title":"Cureus"},{"key":"R19-20260730","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semarthrit.2017.11.003","article-title":"Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases","volume":"48","author":"de Risi-Pugliese","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R20-20260730","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaad.2017.09.059","article-title":"Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis","volume":"78","author":"Chasset","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R21-20260730","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/RHU.0000000000001160","article-title":"Thalidomide and lenalidomide for refractory systemic\/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice","volume":"27","author":"Yuki","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"R22-20260730","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0961203313509295","article-title":"Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis","volume":"22","author":"Duxbury","year":"2013","journal-title":"Lupus"},{"key":"R23-20260730","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of nonrenal systemic lupus erythematosus: a systematic review","volume":"44","author":"Cobo-Ib\u00e1\u00f1ez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"R24-20260730","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1093\/rheumatology\/keaf145","article-title":"Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials","volume":"64","author":"Grosso","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20260730","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/09612033251337130","article-title":"The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: a large pooled post hoc analysis","volume":"34","author":"Manzi","year":"2025","journal-title":"Lupus"},{"key":"R26-20260730","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R27-20260730","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/acr.25058","article-title":"Improvement in cutaneous lupus erythematosus after twenty weeks of belimumab use: a systematic review and meta-analysis","volume":"75","author":"Kneeland","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R28-20260730","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jid.2023.10.039","article-title":"Plasmacytoid dendritic cells are not major producers of type 1 IFN in cutaneous lupus: an in-depth immunoprofile of subacute and discoid lupus","volume":"144","author":"Vazquez","year":"2024","journal-title":"J Invest Dermatol"},{"key":"R29-20260730","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"R30-20260730","doi-asserted-by":"crossref","first-page":"103723","DOI":"10.1016\/j.autrev.2024.103723","article-title":"Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules \u2013 a systematic review and meta-analysis","volume":"24","author":"Bokor","year":"2025","journal-title":"Autoimmun Rev"},{"key":"R31-20260730","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/art.43271","article-title":"Pharmacodynamic effects of litifilimab in lupus in a randomized, placebo-controlled phase 2 study: rapid and sustained reductions in type I interferon-associated gene expression and cytokines","volume":"77","author":"Furie","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R32-20260730","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/BOR.0000000000001003","article-title":"Emerging biologic therapies for systemic lupus erythematosus","volume":"36","author":"Kato","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"R33-20260730","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jaad.2024.09.074","article-title":"Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial","volume":"92","author":"Werth","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R34-20260730","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001705","article-title":"Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7\/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study","volume":"12","author":"Witte","year":"2025","journal-title":"Lupus Sci Med"},{"key":"R35-20260730","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.1021\/acs.jmedchem.5c00463","article-title":"Discovery of edecesertib (GS-5718): a potent, selective inhibitor of IRAK4","volume":"68","author":"Ammann","year":"2025","journal-title":"J Med Chem"},{"key":"R36-20260730","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"R37-20260730","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a posthoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R38-20260730","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/09612033241273023","article-title":"Anifrolumab for systemic lupus erythematosus with multirefractory skin disease: a case series of 18 patients","volume":"33","author":"Flouda","year":"2024","journal-title":"Lupus"},{"key":"R39-20260730","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1093\/ced\/llaf272","article-title":"Anifrolumab for the treatment of cutaneous lupus erythematosus: a 10-case series","volume":"50","author":"Hern\u00e1ndez-Salas","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"R40-20260730","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/S2665-9913(20)30342-8","article-title":"Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study","volume":"3","author":"Bruce","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R41-20260730","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/1346-8138.17354","article-title":"A double-blind pilot study of oral baricitinib in adult patients with lupus erythematosus panniculitis","volume":"51","author":"Chen","year":"2024","journal-title":"J Dermatol"},{"key":"R42-20260730","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"R43-20260730","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jdcr.2021.09.030","article-title":"Oral tofacitinib citrate for recalcitrant cutaneous lupus","volume":"20","author":"Bonnardeaux","year":"2022","journal-title":"JAAD Case Rep"},{"key":"R44-20260730","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"R45-20260730","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40259-020-00405-2","article-title":"Targeted biologic therapy for systemic lupus erythematosus: emerging pathways and drug pipeline","volume":"34","author":"Klavdianou","year":"2020","journal-title":"BioDrugs"},{"key":"R46-20260730","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"61","author":"Werth","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R47-20260730","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R48-20260730","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"R49-20260730","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2013 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"R50-20260730","doi-asserted-by":"crossref","first-page":"1630569","DOI":"10.3389\/fimmu.2025.1630569","article-title":"CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"R51-20260730","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R52-20260730","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"R53-20260730","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1620\/tjem.2022.J074","article-title":"Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus: a case report and review of the literature","volume":"258","author":"Ma","year":"2022","journal-title":"Tohoku J Exp Med"},{"key":"R54-20260730","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"key":"R55-20260730","doi-asserted-by":"crossref","first-page":"e001689","DOI":"10.1136\/lupus-2025-001689","article-title":"Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week phase II study","volume":"12","author":"Romankevych","year":"2025","journal-title":"Lupus Sci Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:00:34Z","timestamp":1785394834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001175","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]}}}